J Cancer 2024; 15(10):3045-3064. doi:10.7150/jca.95311 This issue Cite

Review

Global progress and future prospects of early gastric cancer screening

Yixiao Huang1,2*, Yongfu Shao1,2*, Xuan Yu2, Chujia Chen2, Junming Guo2✉, Guoliang Ye1,3✉

1. Department of Gastroenterology, the First Affiliated Hospital of Ningbo University, Ningbo 315020, China.
2. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo 315211, China.
3. Institute of Digestive Disease of Ningbo University, Ningbo 315020, China.
* These authors contributed equally to this work and should be regarded as co-first authors.

Citation:
Huang Y, Shao Y, Yu X, Chen C, Guo J, Ye G. Global progress and future prospects of early gastric cancer screening. J Cancer 2024; 15(10):3045-3064. doi:10.7150/jca.95311. https://www.jcancer.org/v15p3045.htm
Other styles

File import instruction

Abstract

Graphic abstract

Gastric cancer is a prevalent malignancy that poses a serious threat to global health. Despite advances in medical technologies, screening methods, and public awareness, gastric cancer remains a significant cause of morbidity and mortality worldwide. Early gastric cancer frequently does not present with characteristic symptoms, while advanced stage disease is characterized by a dismal prognosis. As such, early screening in gastric cancer is of great importance. In recent years, advances have been made globally in both clinical and basic research for the screening of early gastric cancer. The current predominant screening methods for early gastric cancer include imaging screening, endoscopic screening and serum biomarker screening. Imaging screening encompasses upper gastrointestinal barium meal, multidimensional spiral computed tomography (MDCT), Magnetic resonance imaging (MRI), and ultrasonography. Endoscopic screening methods include white light endoscopy, chromoendoscopy, computed virtual chromoendoscopy, and other endoscopic techniques like endocytoscopy, confocal laser endomicroscopy, optical coherence tomography and so on. Biomarkers screening involves the assessment of conventional biomarkers such as CEA, CA19-9 and CA72-4 as well as more emerging biomarkers such as peptides (PG, G-17, GCAA, TAAs and others), DNA (cfDNA, DNA methylation, MSI), noncoding RNA (miRNA, lncRNA, circRNA, and tsRNA) and others. Each screening method has its strengths and limitations. This article systematically summarizes worldwide progress and future development of early gastric cancer screening methods to provide new perspectives and approaches for early diagnostic and treatment advancements in gastric cancer worldwide.

Keywords: Gastric cancer, Early screening, Imaging, Endoscopy, Biomarkers, Noncoding RNA


Citation styles

APA
Huang, Y., Shao, Y., Yu, X., Chen, C., Guo, J., Ye, G. (2024). Global progress and future prospects of early gastric cancer screening. Journal of Cancer, 15(10), 3045-3064. https://doi.org/10.7150/jca.95311.

ACS
Huang, Y.; Shao, Y.; Yu, X.; Chen, C.; Guo, J.; Ye, G. Global progress and future prospects of early gastric cancer screening. J. Cancer 2024, 15 (10), 3045-3064. DOI: 10.7150/jca.95311.

NLM
Huang Y, Shao Y, Yu X, Chen C, Guo J, Ye G. Global progress and future prospects of early gastric cancer screening. J Cancer 2024; 15(10):3045-3064. doi:10.7150/jca.95311. https://www.jcancer.org/v15p3045.htm

CSE
Huang Y, Shao Y, Yu X, Chen C, Guo J, Ye G. 2024. Global progress and future prospects of early gastric cancer screening. J Cancer. 15(10):3045-3064.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image